Skip to main content

Table 17 Proportion of responses by level of severity for EQ-5D-5L dimensions at baseline and at 8 month follow-up by treatment

From: The multimorbidity collaborative medication review and decision making (MyComrade) study: a pilot cluster randomised trial in two healthcare systems

 

Intervention

Control

Dimensions

Levels

Baseline

N  = 59

%

Follow-up

8 months

N  = 46

%

Difference baseline to follow-up time

Baseline

N  = 62

%

Follow-up

8 months

N  = 57

%

Difference baseline to follow-up time

Mobility

 

None

38.60

36.96

 − 1.64

19.35

26.32

6.97

 

Slight

26.32

23.91

 − 2.41

29.03

22.81

 − 6.22

 

Moderate

24.56

28.26

3.70

35.48

35.09

 − 0.39

 

Severe

10.53

10.87

0.34

11.29

14.04

2.75

 

Unable

0.00

0.00

0.00

4.84

1.75

 − 3.09

Self-care

 

None

75.44

62.22

 − 13.22

61.29

56.14

 − 5.15

 

Slight

8.77

26.67

17.90

12.90

21.05

8.15

 

Moderate

15.79

8.89

 − 6.90

16.13

17.54

1.41

 

Severe

0.00

2.22

2.22

1.61

1.75

0.14

 

Unable

0.00

0.00

0.00

8.06

3.51

 − 4.55

Usual activities

 

None

38.60

32.61

 − 5.99

20.97

26.32

5.35

 

Slight

24.56

32.61

8.05

33.87

31.58

 − 2.29

 

Moderate

24.56

26.09

1.53

24.19

19.30

 − 4.89

 

Severe

10.53

6.52

 − 4.01

11.29

12.28

0.99

 

Unable

1.75

2.17

0.42

9.68

10.53

0.85

Pain/discomfort

 

None

19.30

31.11

11.81

9.84

17.54

7.70

 

Slight

26.32

13.33

 − 12.99

31.15

22.81

 − 8.34

 

Moderate

33.33

44.44

11.11

32.79

35.09

2.30

 

Severe

17.54

6.67

 − 10.87

21.31

21.05

 − 0.26

 

Extreme

3.51

4.44

0.93

4.92

3.51

 − 1.41

Anxiety/depression

 

None

50.88

52.17

1.29

45.00

37.50

 − 7.50

 

Slight

24.56

26.09

1.53

26.67

30.36

3.69

 

Moderate

24.56

19.57

 − 4.99

20.00

30.36

10.36

 

Severe

0.00

2.17

2.17

8.33

1.79

 − 6.54

 

Extreme

0.00

0.00

0.00

0.00

0.00

0.00